aTyr Pharma
Edit

aTyr Pharma

http://www.atyrpharma.com/
Last activity: 13.11.2023
Categories: ResearchDevelopmentBioTechHumanEstateInformationProductLifePropertyPublic
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
Likes
94
Followers
897
Followers
4.66K
Mentions
81
Location: United States, California, San Diego
Employees: 11-50
Phone: +1 858-731-8389
Total raised: $240.5M

Investors 5

Funding Rounds 7

DateSeriesAmountInvestors
07.02.2023-$50M-
21.11.2016-$20M-
01.04.2015Series E$76M-
29.07.2013-$49M-
26.10.2010Series C$23M-
28.07.2009-$12M-
18.04.2007-$10.5M-

Mentions in press and media 81

DateTitleDescriptionSource
13.11.2023aTyr Pharma Presents Poster Demonstrating Preclinical Effect...Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibros...einpresswi...
09.08.2023aTyr Pharma Announces Second Quarter 2023 Results and Provid...Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Eur...einpresswi...
22.05.2023aTyr Pharma Presents New Data on Efzofitimod Mechanism of Ac.../EIN News/ -- Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells ...einpresswi...
06.02.2023aTyr Pharma Announces Achievement of Development Milestone b.../EIN News/ -- $10M milestone payment triggered by advancement of clinical program in Japan. Multipl...einpresswi...
18.11.2022aTyr Pharma Announces Inducement Grants Under Nasdaq Listing.../EIN News/ -- SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth...einpresswi...
25.10.2022aTyr Pharma to Present at the Jefferies London Healthcare Co.../EIN News/ -- SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth...einpresswi...
25.10.2022aTyr Pharma to Present at the Jefferies London Healthcare Co...SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics com...globenewsw...
13.09.2022aTyr Pharma Receives FDA Fast Track Designation for Efzofiti.../EIN News/ -- Second Fast Track designation for efzofitimod clinical program. Efzofitimod previousl...einpresswi...
13.09.2022aTyr Pharma Receives FDA Fast Track Designation for Efzofiti...Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA...globenewsw...
09.09.2022aTyr Pharma to Present at the Life Sciences Investor Forum o...SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a bi...globenewsw...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In